论文部分内容阅读
目的:探究酒精性胃粘膜损伤患者应用康复新液与雷贝拉唑联合治疗的临床疗效。方法:将88例酒精性胃粘膜损伤患者随机分为观察组合对照组各44例,其中对照患者给予雷贝拉唑治疗,观察组患者在对照组基础上配合康复新液治疗,比较所有患者治疗后的恢复情况以及胃粘膜修复情况。结果:经过7天的治疗观察组上腹痛,呕吐,反酸,黑便消失比例明显高于对照组,差异均有统计学意义(p<0.05)观察组患者的胃粘膜修复率和总有效率明显高于对照组,差异均有统计学意义(p<0.05)。结论:应用康复新液与雷贝拉唑联合治疗酒精性胃粘膜损伤患者,效果理想,安全性高,能有效修复胃粘膜,值得在临床上广泛推广应用。
Objective: To investigate the clinical efficacy of Kangfuxin and Rabeprazole in patients with alcoholic gastric mucosal injury. Methods: 88 cases of alcoholic gastric mucosal injury were randomly divided into observation and control group, 44 cases in each group, of which the control group was treated with rabeprazole, and the observation group was treated with Kangfuxinye on the basis of the control group. All the patients were treated After the recovery and gastric mucosal repair situation. Results: The rate of disappearance of vomit, acid reflux and melena on the 7-day treatment group was significantly higher than that of the control group (p <0.05). The gastric mucosal repair rate and total effective rate Significantly higher than the control group, the difference was statistically significant (p <0.05). Conclusion: The combination of Kangfuxin and rabeprazole in the treatment of patients with alcoholic gastric mucosal injury has good effect and high safety. It can repair gastric mucosa effectively and is worth popularizing widely in clinic.